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Abstract
A modified pan-PV consensus-degenerate hybrid oligonucleotide primer (CODEHOP) PCR was developed for generic and
sensitive detection of a broad-spectrum of human papillomaviruses (HPVs) infecting the cutaneous epithelium. To test the
analytical sensitivity of the assay we examined 149 eyebrow hair follicle specimens from immunocompetent male patients.
HPV DNA was detected in 60% (89/149) of analysed eyebrow samples with a total of 48 different HPV sequences,
representing 21 previously described HPVs and 27 putative novel HPV types. Evidence for ten novel HPV subtypes and seven
viral variants, clustering to three out of five genera containing cutaneous HPVs, was also obtained. Thus, we have shown that
the modified pan-PV CODEHOP PCR assay is able to identify multiple HPV types, even from different genera, in the same
clinical sample. Overall, these results demonstrate that the pan-PV CODEHOP PCR is an excellent tool for screening and
identification of novel cutaneous HPVs, even in samples with low viral loads.
Papillomaviruses (PVs) are a large and diverse group of
small, circular, double-stranded DNA viruses, classified into
genera, species and types based on the comparison of L1
gene nucleotide sequences [1]. PVs infecting humans
(HPVs) are grouped within five genera (Alpha-PV, Beta-
PV, Gamma-PV,Mu-PV and Nu-PV), with mucosal/genital
HPV types mostly clustering within the Alpha-PV genus.
Cutaneous HPV types, representing approximately 75% of
all officially described HPVs to date, are highly divergent
and are distributed into all five HPV genera [2].
HPVs are aetiologically linked with the development of vari-
ous benign and malignant lesions of the skin and mucosa
[3]. The mucosal high-risk HPVs (HPV16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58 and 59) are associated with the devel-
opment of more than 99% of cervical cancers, 70–90% of
anal and vaginal cancers, 47% of penile cancers, 40% of
vulvar cancers and 25–30% of oropharyngeal cancers.
Mucosal low-risk HPV types, most commonly HPV6 and
11, are associated with more than 90% of anogenital warts
and laryngeal papillomas [4]. However, the role of cutane-
ous HPV types in skin cancer is still unclear. Cutaneous
HPVs have not only been found in benign skin warts and
non-melanoma skin cancer [5–7], but also on healthy skin
worldwide [8–11]. Continued efforts to improve identifica-
tion of novel cutaneous HPVs could lead to a better
Received 2 October 2017; Accepted 30 November 2017
Author affiliations:
1Grupo Virología Humana, Instituto de Biología Molecular y Celular de Rosario (CONICET), Suipacha 590, 2000 Rosario, Argentina;
2Área Virología, Facultad de Ciencias Bioquímicas y Farmaceuticas, Universidad Nacional de Rosario, Suipacha 531, 2000 Rosario, Argentina; 3Institute of
Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1105 Ljubljana, Slovenia; 4Center for Global Infectious Disease
Research, Seattle Children’s Research Institute, Seattle, WA, USA.
*Correspondence: Mario Poljak, mario.poljak@mf.uni-lj.si
Keywords: CODEHOP; human papillomavirus; HPV; multiple infections.
Abbreviations: CODEHOP, consensus-degenerate hybrid oligonucleotide primer; HPV, human papillomavirus; I, inosine; MCMC, Markov chain
Monte Carlo; PV, papillomavirus.
†These authors contributed equally to this work.
The GenBank/EMBL/DDBJ accession numbers for nucleotide sequences of novel/putative HPV types reported in this paper are: SIBX22 (LK022298),
SIBX23 (LK022299), SIBX24 (LK022300), SIBX25 (LK022301), SIBX26 (LK022302), SIBX27 (LK022303), SIBX28 (LK022304), SIBX29 (LK022305),
SIBX30 (LK022306), SIBX31 (LK022307), SIBX32 (LK022308), SIBX33 (LK022309), SIBX34 (LK022310), SIBX35 (LK022311), SIBX36 (LK022312),
SIBX37 (LK022313), SIBX38 (LK022314), SIBX39 (LK022315), SIBX40 (LK022316), SIBX41 (LK022317), SIBX42 (LK022318), SIBX43 (LK022319),
SIBX44 (LK022320), SIBX45 (LK022321), SIBX46 (LK022322), SIBX47 (LK022323), SIBX48 (LK022324), SIBX49 (LK022325), SIBX50 (LK022326),
SIBX51 (LM653099), SIBX52 (LM653100), SIBX53 (LM653101), SIBX54 (LM653102), SIBX55 (LM653103), SIBX56 (LM653104), SIBX57 (KP768215),
SIBX58 (KP768216), SIBX59 (KP768217), SIBX60 (KP768218), SIBX61 (KP768219), SIBX62 (KP768220), SIBX63 (KP768221), SIBX64 (KP768222),
SIBX65 (KP768223).
SHORT COMMUNICATION
Chouhy et al., Journal of General Virology 2018;99:109–118
DOI 10.1099/jgv.0.000988
000988 ã 2018 The Authors
109
Downloaded from www.microbiologyresearch.org by
IP:  217.46.74.140
On: Tue, 13 Feb 2018 10:12:44
understanding of their phylogenetic diversity and clarifica-
tion of their role in the development of skin cancer. Due to
the extraordinary diversity of HPVs infecting the skin [12],
the development of primer sets enabling amplification of a
diverse range of HPV types is critical for this effort.
Over the past years, the sensitivity of molecular methods for
detection of HPV infections has increased significantly.
However, the majority of assays only detect infection with
HPV types or species within a single genus. Only a few
methods have demonstrated the ability to detect a broad-
range of HPV types from different species and genera
[13–15]. Traditionally, simple PCR assays using single or
multiple pairs of degenerate primers or nested PCR assays
using two pairs of degenerate primers were employed for
identification and characterization of novel PVs [16]. Previ-
ously, we devised the consensus-degenerate hybrid oligonu-
cleotide primer (CODEHOP) for broad-range detection of
all members of a gene family [17], and have utilized this
approach for novel virus identification [18]. We developed a
pan-PV CODEHOP PCR-based assay to detect multiple
HPV types distributed over all five PV genera in different
types of warts as well as precancerous and cancerous lesions
of the cervix [19, and personal communication]. However,
the detection of HPVs was more challenging in eyebrow
hair follicles because of frequent co-infections with multiple
HPV types as well as low viral copy numbers. In this study,
an improved version of the original pan-PV CODEHOP pri-
mers was used in a combination with a single-tube ‘hanging
droplet’ PCR [20] to survey cutaneous HPV types in eye-
brow samples.
The ‘hanging droplet’ pan-PV CODEHOP PCR was
designed as a ‘re-amplification PCR’ in which the same pri-
mers were used in both rounds of amplifications, as
reported previously [15, 21]. All reactions were set up on a
Mastercycler proS thermal cycler (Eppendorf, Germany)
and performed with a HotStarTaq Plus DNA Polymerase
kit (Qiagen, Germany). The primary 20 µl reaction mixture
was placed in a reaction tube and covered with one drop of
mineral oil (Sigma-Aldrich, USA). After addition of 5 µl of
the sample, the mixture had a final volume of 25 µl, contain-
ing 0.2 µM of each forward CODEHOP primer, DGDM_F1
(5¢-GAG CTT ATA AAC ACA GAT ATT GAA GAT GGI
GAY ATG-3¢) (I, inosine) and DGDM_F2 (5¢-GAG CTT
ATA AAC ACA GTT ATT GAG GAY GGN GAY ATG-
3¢), 0.4 µM of the reverse CODEHOP primer PAP14_R (5¢-
GTA ACA AAC ACC TGG TTA CCC CAA CAG ATI
CCA TTR TT-3¢), 400 µM of each dNTP (PCR Nucleotide
Mix; Roche Diagnostics, Germany), 1X CoralLoad PCR
Buffer, 2mM of MgCl2 and 0.625 U of HotStarTaq Plus
DNA polymerase. In addition, 25 µl of the above-mentioned
reaction mixture, including fresh DNA polymerase (1 U)
and all three primers at the same concentrations, were
loaded onto the inside of each reaction tube cap forming a
‘hanging droplet’ when the reaction cap was closed. Using
the thermocycler without the heated lid, a first round of
amplification was performed, in which the reaction mixture
was first heated for 5min at 95

C, followed by 25 cycles of
1min at 94

C, 1min at 50

C and 1min at 72

C, followed
by a final elongation step of 10min at 72

C. For the second
round of amplification, the ‘hanging droplet’ was incorpo-
rated into the reaction mixture (final volume of 50 µl) using
a quick centrifugation step (1min at 2000 g), and 45 ampli-
fication cycles were performed using the same cycling con-
ditions as for the first round of PCR.
The sensitivity and specificity of the optimized assay were
evaluated on cloned DNA of several HPV types from
Alpha-PV (HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 56, 58
and 59), Beta-PV (HPV150) and Gamma-PV (HPV4, 156
and 179) genera, at input levels of 5, 50, 500 and 1000 viral
copies per reaction in a background of 50 ng of human pla-
cental DNA (Sigma) or human genomic DNA (Thermo
Fisher Scientific). Non-specific amplification was tested
using five replicates of 20, 50, 100 and 200 ng of human
genomic DNA (Thermo Fisher Scientific) per reaction. The
analytical sensitivity of the assay was determined to be five
copies per reaction for HPV16 and 18, 50 copies per reac-
tion for HPV6, 11, 33, 35, 45, 52, 56, 58, 66 and 179, and
500 copies per reaction for HPV4, 31, 39, 59, 150 and 156.
These results indicated that the pan-PV CODEHOP PCR-
based assay was a sensitive tool for broad-based HPV-
screening in clinical samples with low viral copy numbers.
In order to analyse the ability of the pan-PV CODEHOP
PCR to identify multiple HPV infections, a total of 149
pooled eyebrow hair follicle specimens, containing from 5
to 8 hairs each, were obtained from 149 immunocompetent
male patients with clinically evident anogenital warts, as
described previously [22]. The study was approved by the
Institutional Review Board of the Ministry of Health of
Republic of Slovenia (consent reference 97/11/09). All
patients additionally provided a written informed consent
and were sampled in compliance with the Helsinki Declara-
tion. Total DNA was extracted from all specimens as
described previously [22] and the quality of all DNA sam-
ples was verified by real-time PCR amplification of a 150 bp
fragment of the human beta-globin gene [23].
The PCR products obtained using the pan-PV CODEHOP
PCR-based assay (360–380 bp) were visualized by 2% agar-
ose gel electrophoresis, purified with a QIAquick PCR puri-
fication kit or in the case of multiple bands using the
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany).
Both strands of each amplicon were sequenced using the
same primers as for PCR at Microsynth AG (Balgach,
Switzerland).
All HPV-specific amplicons were additionally cloned into
pJET1.2/blunt cloning vectors using the CloneJET PCR
Cloning Kit (Thermo Fisher Scientific). HPV plasmids were
then transformed into One Shot TOP10 Chemically
Competent E. coli cells (Invitrogen, USA), as per the manu-
facturer’s instructions. Clones containing targeted inserts
were identified using colony PCR, performed with the Fast-
Start PCR Master (Roche Diagnostics) and primers specific
Chouhy et al., Journal of General Virology 2018;99:109–118
110
Downloaded from www.microbiologyresearch.org by
IP:  217.46.74.140
On: Tue, 13 Feb 2018 10:12:44
Table 1. HPV sequences identified in eyebrow hair follicles using the pan-PV CODEHOP PCR
HPV/SIBX sequence HPV species Novel sequence Closely related type (%) No. of positive samples
(Accesion no.) Type Subtype Variant (Prevalence, %)
HPV6 (X00203) Alpha-10 x 1 (0.7%)
HPV11 (M14119) Alpha-10 x 1 (0.7%)
HPV5 (M17463) Beta-1 x 1 (0.7%)
HPV12 (X74466) Beta-1 x 17 (11.4%)
HPV21 (U31779) Beta-1 x 2 (1.3%)
HPV24 (U31782) Beta-1 x 1 (0.7%)
HPV118 (GQ246951) Beta-1 x 1 (0.7%)
HPV124 (GQ845446) Beta-1 x 1 (0.7%)
HPVRTRX7 (U85660) Beta-1 x 1 (0.7%)
SIBX22 (LK022298) Beta-1 x HPV118 (88.0%) 3 (2.0%)
SIBX25 (LK022301) Beta-1 x HPV124 (91.3%) 3 (2.0%)
SIBX62 (KP768220) Beta-1 x HPV12 (93.2%) 1 (0.7%)
SIBX65 (KP768223) Beta-1 x HPV124 (88.9%) 1 (0.7%)
HPV9 (X74464) Beta-2 x 8 (5.4%)
HPV15 (X74468) Beta-2 x 9 (6.0%)
HPV37 (U31786) Beta-2 x 2 (1.3%)
HPV38 (U31787) Beta-2 x 1 (0.7%)
HPV174 (HF930491) Beta-2 x 4 (2.7%)
HPV122 (GQ845444) Beta-2 x 4 (2.7%)
SIBX26 (LK022302) Beta-2 x HPV113 (84.1%) 3 (2.0%)
SIBX29 (LK022305) Beta-2 x HPV209 (97.4%) 3 (2.0%)
SIBX61 (KP768219) Beta-2 x HPV174 (86.1%) 1 (0.7%)
SIBX63 (KP768221) Beta-2 x HPV174 (94.1%) 1 (0.7%)
HPV75 (Y15173) Beta-3 x 4 (2.7%)
HPV115 (FJ947080) Beta-3 x 1 (0.7%)
SIBX59 (KP768217) Beta-3 x HPV76 (96.6%) 2 (1.3%)
SIBX64 (KP768222) Beta-3 x SIBX59 (97.6%) 1 (0.7%)
HPV150 (FN677755) Beta-5 x 3 (2.0%)
SIBX54 (LM653102) Beta-5 x HPV96 (83.0%) 7 (4.7%)
SIBX42 (LK022318) Gamma-1 x HPV158 (83.6%) 1 (0.7%)
SIBX44 (LK022320) Gamma-1 x SIBX42 (99.7%) 1 (0.7%)
SIBX45 (LK022321) Gamma-1 x HPV158 (83.3%) 10 (6.7%)
SIBX33 (LK022309) Gamma-8 x mSE37 (75.2%) 1 (0.7%)
SIBX37 (LK022313) Gamma-8 x SIBX33 (97.9%) 1 (0.7%)
SIBX35 (LK022311) Gamma-9 x HPV129 (73.4%) 1 (0.7%)
HPV142 (HM999994) Gamma-10 x 1 (0.7%)
SIBX39 (LK022315) Gamma-10 x HPV142 (85.4%) 11 (7.4%)
SIBX57 (KP768215) Gamma-11 x HPV126 (89.5%) 1 (0.7%)
SIBX60 (KP768218) Gamma-11 x SIBX57 (98.4%) 2 (1.3%)
HPV165 (JX444072) Gamma-12 x 1 (0.7%)
SIBX23 (LK022299) Gamma-12 x mCG3 (78.6%) 2 (1.3%)
SIBX27 (LK022303) Gamma-12 x mCG3 (86.5%) 5 (3.4%)
SIBX34 (LK022310) Gamma-12 x HPV165 (80.2%) 1 (0.7%)
SIBX40 (LK022316) Gamma-12 x HPV157 (77.9%) 2 (1.3%)
SIBX41 (LK022317) Gamma-12 x SIBX40 (99.3%) 3 (2.0%)
SIBX50 (LK022326) Gamma-12 x HPV157 (99.7%) 1 (0.7%)
SIBX43 (LK022319) Gamma-15 x HPV179 (78.3%) 2 (1.3%)
SIBX38 (LK022314) Gamma-17 x HPV144 (75.8%) 1 (0.7%)
SIBX24 (LK022300) Gamma-18 x HPV156 (87.3%) 1 (0.7%)
HPV161 (JX413109) Gamma-19 x 1 (0.7%)
SIBX47 (LK022323) Gamma-19 x HPV166 (92.3%) 3 (2.0%)
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for the plasmid (pJET1.2 Forward Sequencing and pJET1.2
Reverse Sequencing Primers; Thermo Fisher Scientific).
Positive clones were sequenced on both strands using
pJET1.2 sequencing primers at Microsynth AG (Balgach,
Switzerland). All obtained nucleotide sequences were com-
pared to HPV sequences available in the GenBank database,
using the BLAST server (www.ncbi.nlm.nih.gov/blast/). Novel
putative HPV types, subtypes and viral variants were identi-
fied when their L1 nucleotide sequences showed less than
90%, between 90 and 98%, or between 98 and 99%
sequence identities with all previously known HPV types,
respectively [1]. Results of the BLAST comparison were addi-
tionally verified by aligning the sequences of interest with
L1 nucleotide sequences of the most closely related HPVs
using the MEGA software, version 7 [24]. Nucleotide sequen-
ces indicating the presence of novel HPV types/subtypes/
variants were subsequently assigned their in-house SIBX
identifying numbers and submitted to the GenBank
database.
Full-length L1 ORFs from 180 reference HPV types (www.
hpvcenter.se) and 19 completely sequenced but officially
unrecognized HPV genomes (obtained mostly by metage-
nomics) were included in the phylogenetic analysis of puta-
tively novel HPV types/subtypes/variants obtained in the
present study. Multiple alignments and pairwise nucleotide
alignments were performed with MEGA v7 [24]. Phylogenetic
trees were inferred by the Bayesian method using BEAST
v1.8.4 [25] and Markov chain Monte Carlo (MCMC) simu-
lations were performed during 2107 generations, sampling
one state every 1000 generations, with a burn-in of 10%.
Statistical convergence of MCMC was assessed by calculat-
ing the effective sample size using TRACER v1.6 (http://beast.
community/tracer). The maximum clade credibility tree
across all of the plausible trees generated by BEAST was then
computed using the TreeAnnotator program available in
the BEAST package.
Using the modified pan-PV CODEHOP PCR-based assay,
the overall HPV prevalence in eyebrow hair follicle speci-
mens was estimated at 60% (89/149), which is similar to
other studies using different generic or genus-specific
primer pairs [22, 26]. On the other hand, in other studies, in
which a combination of PCR amplification of short ampli-
cons followed by reverse hybridization or microarrays was
used for the identification of HPV types, the HPV preva-
lence was estimated at >80% [27–29]. These methods gen-
erally improve the rate of HPV detection in comparison to
amplicon detection using agarose gel electrophoresis fol-
lowed by HPV typing by sequencing, but reverse hybridiza-
tion techniques and microarrays only allow the
identification of a limited number of HPV types. In our
study, a total of 48 different HPV isolates were identified,
representing 21 previously described HPV types and 27
putative novel HPV types (SIBX isolates), clustering within
three of the five genera containing cutaneous HPVs
(Table 1). Moreover, the pan-PV CODEHOP PCR detected
sequences representing ten novel putative HPV subtypes
and seven novel viral variants.
The phylogenetic relationships of all identified SIBX
sequences and their type/subtype/variant-specific prevalen-
ces are provided in Table 1. The most frequently detected
HPV sequences, which were identified in eight or more
clinical samples, included HPV9 (Beta-2), HPV12 (Beta-1),
HPV15 (Beta-2), SIBX28 (Gamma-24), SIBX31 (Gamma-
24), SIBX39 (Gamma-10), SIBX45 (Gamma-1), SIBX46
(Gamma-24) and SIBX48 (Gamma-24). Even though
Table 1. cont.
HPV/SIBX sequence HPV species Novel sequence Closely related type (%) No. of positive samples
(Accesion no.) Type Subtype Variant (Prevalence, %)
SIBX49 (LK022325) Gamma-19 x HPV166 (86.1%) 1 (0.7%)
SIBX51 (LM653099) Gamma-19 x mZJ01 (74.9%) 2 (1.3%)
SIBX55 (LM653103) Gamma-19 x SIBX51 (99.7%) 7 (4.7%)
SIBX58 (KP768216) Gamma-19 x HPV166 (84.8%) 1 (0.7%)
SIBX56 (LM653104) Gamma-20 x HPV163 (80.8%) 5 (3.4%)
SIBX28 (LK022304) Gamma-24 x mFD1 (83.0%) 14 (9.4%)
SIBX30 (LK022306) Gamma-24 x mSE355 (79.3%) 4 (2.7%)
SIBX31 (LK022307) Gamma-24 x mFD1 (83.9%) 16 (10.7%)
SIBX32 (LK022308) Gamma-24 x SIBX31 (99.7%) 1 (0.7%)
SIBX36 (LK022312) Gamma-24 x mFD1 (86.3%) 1 (0.7%)
SIBX46 (LK022322) Gamma-24 x SIBX31 (97.9%) 8 (5.4%)
SIBX48 (LK022324) Gamma-24 x mKN1 (99.1%) 8 (5.4%)
SIBX52 (LM653100) Gamma-24 x SIBX30 (91.0%) 1 (0.7%)
SIBX53 (LM653101) Gamma-24 x HPV197 (80.2%) 6 (4.0%)
TOTAL 48 10 7
SIBX, novel putative HPV types/subtypes/variants identified in this study.
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previous studies similarly observed that Beta- and Gamma-
PVs are highly prevalent in eyebrow samples [22, 26–29], a
direct comparison of type-specific prevalence across
studies is difficult due to methodological differences [15,
22, 26–32].
Phylogenetic clustering of the pan-PV CODEHOP PCR
amplicons matched the clustering described previously by
other authors [33]. The phylogenetic analysis and pairwise
comparisons revealed that all SIBX sequences were clustered
within defined species of Beta-PV and Gamma-PV genera.
Eleven SIBX sequences grouped within the Beta-PV genus.
Five represented novel putative HPV types and six repre-
sented novel putative HPV subtypes (Fig. 1, Table 1). The
majority of SIBX sequences (33/44; 75%) clustered within
the Gamma-PV genus. Twenty-two represented novel puta-
tive HPV types, four represented novel putative HPV sub-
types and seven represented novel putative HPV variants.
Since each CODEHOP includes a pool of extra-long pri-
mers with two distinct domains, degenerate core and con-
































Fig. 1. Phylogenetic comparison of putatively novel HPV sequences detected in this study compared to classified reference HPV
sequences. Dots highlight the SIBX isolates. Node values represent Bayesian posterior probability values.
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Table 2. Alignment of pan-PV CODEHOP primers with HPV types used for the analysis of the assay’s analytical sensitivity and those identified in
eyebrow hair follicle specimens, respectively, and type-specific melting temperatures of individual primers
HPV types used for the analysis of the assay’s analytical sensitivity are shown in bold. The degenerated cores of pan-PV CODEHOP primers are
highlighted in grey.
No. of mismatches














HPV18 Alpha-7 5 0 5 - - a - - - - a - - - - - - - - t - t - g - - - - - - - - - - - - - - - 52.1
HPV16 Alpha-9 5 0 5 - - - t - a - - - - - - - - - - t - - - - c - g - - - - - - - - - - - - 51.2
HPV56 Alpha-6 10 0 50 - c a t - a - - t - - t - - - c c - - - a - - g - - - - - - - - - - - - 37.5
HPV66 Alpha-6 14 1 50 - c a t - a g - t - - t - - c c c g - - a - - g - - c - - - - - - - - - 10.3
HPV45 Alpha-7 6 0 50 - - a - - - - a - - - - - - c a t - - - - - - g - - - - - - - - - - - - 49.0
HPV33 Alpha-9 6 0 50 - - a - - - - - - - - t - - t a t - - - - - - g - - - - - - - - - - - - 46.5
HPV35a Alpha-9 10 1 50 - - - t - a c - - - - - - - t - t a c - a c - - - - c - - - - - - - - - 25.4
HPV52 Alpha-9 10 0 50 c - - - - c - - t - - - - g t - t a - - a c - g - - - - - - - - - - - - 33.5
HPV58 Alpha-9 9 0 50 - - a - - - t - t - - t t - t a t - - - - - - g - - - - - - - - - - - - 46.5
HPV6* Alpha-10 9 0 50 - - a - - - - - t - c - - g t - t - - - a c - g - - - - - - - - - - - - 33.5
HPV11* Alpha-10 9 0 50 - - a - - - - - t - c - - g t - t - - - a c - g - - - - - - - - - - - - 33.5
HPV179 Gamma-15 13 0 50 c - a t - a g - - - - t t - t c c a - - - c - g - - - - - - - - - - - - 33.5
HPV4 Gamma-1 6 0 500 - - - - - - g - - - - t t - - t - c - - - c - - - - - - - - - - - - - - 40.8
HPV31 Alpha-9 9 0 500 - - a t - a - a - - - t t - - - t - - - a c - - - - - - - - - - - - - - 40.8
HPV39 Alpha-7 7 0 500 - - a - - a g - - - - - - - c c c - - - - - - g - - - - - - - - - - - - 48.1
HPV59 Alpha-7 7 0 500 - - a t - a - - - - - t - - - c c a - - - - - - - - - - - - - - - - - - 54.0
HPV150* Alpha-5 9 0 500 - - a t - a - a g - - t - - - a t c - - - - - - - - - - - - - - - - - - 53.8
HPV156 Gamma-18 10 0 500 - - a t - a t - t c - - - - t t - c - - - c - - - - - - - - - - - - - - 40.8
HPV5 Beta-1 5 0 - - a - - a - a - - - - - - - t - - - - a - - - - - - - - - - - - - - -
HPV12 Beta-1 8 0 - - - t - a - a g - - - - - t t t c - - - - - - - - - - - - - - - - - -
HPV21 Beta-1 10 0 - - a t - a - - t - - t t - - - c a - - a c - - - - - - - - - - - - - -
HPV24 Beta-1 9 0 a - - t - a g - - - - t t - - - t a - - - c - - - - - - - - - - - - - -
HPV118 Beta-1 12 1 - - a t - g g - g - - t - - t t t - - - - c - g - - - - a - - - - - - -
HPV124 Beta-1 8 0 - - - - - - g - - - - t t - - t - c - - a c - g - - - - - - - - - - - -
HPVRTRX7 Beta-1 7 0 - - a t - a - a - - - - - - t t t - - - - - - - - - - - - - - - - - - -
HPV9 Beta-2 7 0 - - a t - a - g - - - - - - - - t a - - - - - g - - - - - - - - - - - -
HPV15 Beta-2 4 0 - - a - - - - a - - - t - - - - t - - - - - - - - - - - - - - - - - - -
HPV37 Beta-2 6 0 - - a t - a - a - - - - - - - - t g - - - - - - - - - - - - - - - - - -
HPV38 Beta-2 10 1 - - a t - g - a - - - t - g t - t a - - - - - - - - c - - - - - - - - -
HPV122 Beta-2 7 0 - - - t - a - a - - - t t - - - t a - - - - - - - - - - - - - - - - - -
HPV174 Beta-2 7 0 - - a t - a - a - - - - - - t - t - - - - - - g - - - - - - - - - - - -
HPV75 Beta-3 7 0 - - a t - a g - - - - t - - - - t - - - - - - g - - - - - - - - - - - -
HPV115 Beta-3 9 0 - - a t - a - g - - - t - - t a t - - - - - - g - - - - - - - - - - - -
HPV142 Gamma-10 10 0 - - a - - g - a - c - t - g t - t c - - a - - - - - - - - - - - - - - -
HPV161 Gamma-19 12 0 - - a a g a - a - - c a - - t - t a - - - c - g - - - - - - - - - - - -
HPV165 Gamma-12 12 0 c - - t - a g - t g - t - a t - t - - - - c - g - - - - - - - - - - - -
No. of mismatches














HPV18 Alpha-7 5 0 5 - - a - - - - a - - - - - - - - - - t - g - - a - - - - - - - - - - - - 47.6
HPV16 Alpha-9 3 0 5 - - - t - a - - - - - - - - - - - - - - - c - - - - - - - - - - - - - - 61.8
HPV56 Alpha-6 9 0 50 - c a t - a - - t - - t - - - c c - - - a - - - - - - - - - - - - - - - 43.6
HPV66 Alpha-6 12 0 50 - c a t - a g - t - - t - - c c c g - - a - - - - - - - - - - - - - - - 43.6
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Table 2. cont.
No. of mismatches














HPV45 Alpha-7 4 0 50 - - a - - - - a - - - - - - c a - - - - - - - - - - - - - - - - - - - - 55.9
HPV33 Alpha-9 4 0 50 - - a - - - - - - - - t - - t a - - - - - - - - - - - - - - - - - - - - 54.4
HPV35a Alpha-9 9 0 50 - - - t - a c - - - - - - - t - - a c - a c - a - - - - - - - - - - - - 31.8
HPV52 Alpha-9 8 0 50 c - - - - c - - t - - - - g t - - a - - a c - - - - - - - - - - - - - - 34.0
HPV58 Alpha-9 7 0 50 - - a - - - t - t - - t t - t a - - - - - - - - - - - - - - - - - - - - 52.6
HPV6* Alpha-10 7 0 50 - - a - - - - - t - c - - g t - - - - - a c - - - - - - - - - - - - - - 34.0
HPV11* Alpha-10 7 0 50 - - a - - - - - t - c - - g t - - - - - a c - - - - - - - - - - - - - - 34.0
HPV179 Gamma-15 12 0 50 c - a t - a g - - - - t t - t c c a - - - c - - - - - - - - - - - - - - 34.0
HPV4 Gamma-1 8 0 500 - - - - - - g - - - - t t - - t a c - - - c - a - - - - - - - - - - - - 12.2
HPV31 Alpha-9 9 0 500 - - a t - a - a - - - t t - - - - - - - a c - a - - - - - - - - - - - - 23.6
HPV39 Alpha-7 6 0 500 - - a - - a g - - - - - - - c c c - - - - - - - - - - - - - - - - - - - 51.7
HPV59 Alpha-7 8 0 500 - - a t - a - - - - - t - - - c c a - - - - - a - - - - - - - - - - - - 33.5
HPV150* Alpha-5 9 0 500 - - a t - a - a g - - t - - - a - c - - - - - a - - - - - - - - - - - - 33.1
HPV156 Gamma-18 12 0 500 - - a t - a t - t c - - - - t t a c - - - c - a - - - - - - - - - - - - 18.0
HPV5 Beta-1 7 0 - - a - - a - a - - - - - - - t a - - - a - - a - - - - - - - - - - - -
HPV12 Beta-1 8 0 - - - t - a - a g - - - - - t t - c - - - - - a - - - - - - - - - - - -
HPV21 Beta-1 11 0 - - a t - a - - t - - t t - - - c a - - a c - a - - - - - - - - - - - -
HPV24 Beta-1 9 0 a - - t - a g - - - - t t - - - - a - - - c - a - - - - - - - - - - - -
HPV118 Beta-1 10 1 - - a t - g g - g - - t - - t t - - - - - c - - - - - - a - - - - - - -
HPV124 Beta-1 8 0 - - - - - - g - - - - t t - - t a c - - a c - - - - - - - - - - - - - -
HPVRTRX7 Beta-1 7 0 - - a t - a - a - - - - - - t t - - - - - - - a - - - - - - - - - - - -
HPV9 Beta-2 5 0 - - a t - a - g - - - - - - - - - a - - - - - - - - - - - - - - - - - -
HPV15 Beta-2 4 0 - - a - - - - a - - - t - - - - - - - - - - - a - - - - - - - - - - - -
HPV37 Beta-2 6 0 - - a t - a - a - - - - - - - - - g - - - - - a - - - - - - - - - - - -
HPV38 Beta-2 9 0 - - a t - g - a - - - t - g t - - a - - - - - a - - - - - - - - - - - -
HPV122 Beta-2 7 0 - - - t - a - a - - - t t - - - - a - - - - - a - - - - - - - - - - - -
HPV174 Beta-2 5 0 - - a t - a - a - - - - - - t - - - - - - - - - - - - - - - - - - - - -
HPV75 Beta-3 5 0 - - a t - a g - - - - t - - - - - - - - - - - - - - - - - - - - - - - -
HPV115 Beta-3 7 0 - - a t - a - g - - - t - - t a - - - - - - - - - - - - - - - - - - - -
HPV142 Gamma-10 10 0 - - a - - g - a - c - t - g t - - c - - a - - a - - - - - - - - - - - -
HPV161 Gamma-19 10 0 - - a a g a - a - - c a - - t - - a - - - c - - - - - - - - - - - - - -
HPV165 Gamma-12 10 0 c - - t - a g - t g - t - a t - - - - - - c - - - - - - - - - - - - - -
No. of mismatches














HPV18 Alpha-7 9 2 5 - - - - - - - - - g - t - - c - - - c a - - - t - - a t - a - - - - - - - - 61.2
HPV16 Alpha-9 4 1 5 - - - - - - - - - - - t - - - - - - - - - - - - - - a c - a - - - - - - - - 59.0
HPV56 Alpha-6 6 1 50 - - - - - - - - - - - t - - c - - - - - - - - t - - a t - a - - - - - - - - 65.3
HPV66 Alpha-6 4 1 50 - - - - - - - - - - - a - - c - - - - - - - - t - - - - - a - - - - - - - - 47.6
HPV45 Alpha-7 5 1 50 - - - - - - - - - - - t - - - - - - c a - - - t - - - t - - - - - - - - - - 60.3
HPV33 Alpha-9 4 1 50 - - - - - - - - - - - t - - - - - - - - c - - t - - - - - a - - - - - - - - 55.1
HPV35a Alpha-9 4 1 50 - - - - - - - - - - - t - - - - - - a - - - - - - - a t - - - - - - - - - - 64.4
HPV52 Alpha-9 5 1 50 - - - - - - - - - - - a - - - - - - - - c - - t - - - t - - - - - - - c - - 55.8
HPV58 Alpha-9 6 1 50 - - - - - - - - - - - t - - c - - - - - c - - t - - - t - a - - - - - - - - 51.2
HPV6* Alpha-10 4 1 50 - - - - - - - - - - - t - - - - - - - - - - - t - - a c - - - - - - - - - - 77.7
HPV11* Alpha-10 5 1 50 - - - - - - - - - - - t - - c - - - - - a - - - - - c t - - - - - - - - - - 62.9
HPV179 Gamma-15 11 1 50 - - - - - - - - - - - t - - c - - - t c c - - t g - c t - a - - - a - - - - 55.7
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late PCR cycles due to dynamically changing and complex
binding interactions, the differences in the sensitivity of the
assay for different HPV types are hard to model using
straightforward thermodynamic methods [17–19]. As
shown in Table 2, the mentioned differences cannot be
explained solely based on the number of nucleotide mis-
matches (not in the complete primer sequence nor the core
part of the sequence) and/or the primer’s melting tempera-
tures. The observed twofold differences in the analytical
sensitivity of the assay are, therefore, most probably a conse-
quence of reaction conditions, suggesting that even though
the primer design might theoretically be perfect, their per-
formance in the assay must be determined empirically.
In order to determine the ability of the modified pan-PV
CODEHOP PCR to amplify multiple HPV types within the
same sample, multiple clones of the pan-PV amplicons were
sequenced. Single HPV infections were detected in 33/89
(37%) tested samples. The majority of eyebrow hair follicle
specimens (56/89; 63%) contained multiple HPV sequen-
ces, with HPV types from two different genera detected in
53% (30/56) of samples with multiple HPV infections.
In total, 25 clinical samples contained sequences from two
different HPV species, 17 samples contained sequences
from three different HPV species, six samples contained
sequences from four different HPV species and three sam-
ples contained sequences from five different HPV species.
Over two-thirds of HPV-positive eyebrow specimens (64/
89; 72%) contained sequences representing potentially
novel HPV types/subtypes/variants, of which 81% (52/64)
were identified in multiple infections. Officially recognized
HPV types were detected in 60% (53/89) of HPV-positive
samples, with 60% (32/53) of those same samples contain-
ing a co-infection.
Even though as many as 8–12 cloned amplicons were
sequenced for each HPV-positive clinical sample, the num-
ber of samples with multiple infections was probably under-
estimated, since amplicon cloning was not performed or
failed for 10 samples. Deep sequencing techniques may be
necessary to identify all HPV sequences amplified by the
pan-PV CODEHOP PCR within a single sample [33].
Continued efforts to improve the identification of novel
cutaneous HPVs are crucial for a better understanding of
HPV phylogenetic diversity and a clarification of their role
in the development of skin cancer. In the current study, we
have shown that the modified pan-PV CODEHOP PCR
Table 2. cont.
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HPV4 Gamma-1 4 1 500 - - - - - - - - - - - t - - - - - - - a - - - t - - - t - - - - - - - - - - 60.2
HPV31 Alpha-9 5 1 500 - - - - - - - - - - - t - - - - - - - - c - - t - - - t - a - - - - - - - - 47.6
HPV39 Alpha-7 8 1 500 - - - - - - - - - - - a - - - - - - c a - - - t - - a t - a - - - c - - - - 40.8
HPV59 Alpha-7 9 1 500 - - - - - - - - - - - a - - - - - - c a c - - t - - a t - - - - - t - a - - 48.9
HPV150* Alpha-5 7 1 500 - - - - - - - - - - - t - - - - - - - - - - - t - - a a - c - - - t - a - - 64.8
HPV156 Gamma-18 9 1 500 - - - - - - - - - - - a c t - - - - - - - - - - - - a t g t - - - a - a - - 61.5
HPV5 Beta-1 9 0 - - - - - - - - - - - - c t g - - - - c - - - t - - a a - - - - - a - c - -
HPV12 Beta-1 7 0 - - - - - - - - - - - - c t g - - - - c - - - t - - - a - - - - - - - c - -
HPV21 Beta-1 7 1 - - - - - - - - - - - a - - - - - - t t - - - t - - a t - a - - - - - - - -
HPV24 Beta-1 7 1 - - - - - - - - - - - t - - - - - - - c - - - t - - a t - - - - c a - - - -
HPV118 Beta-1 7 0 - - - - - - - - - - - - - t a - - - - - - - - t - - a t - a - - - - - g - -
HPV124 Beta-1 6 0 - - - - - - - - - - - - - t a - - - - - - - - t - - a t - - - - - - - g - -
HPVRTRX7 Beta-1 8 1 - - - - - - - - - - - t c t g - - - - c - - - t - - - a - - - - - - - c - -
HPV9 Beta-2 6 1 - - - - - - - - - - - t - t a - - - - - - - - t - - - a - a - - - - - - - -
HPV15 Beta-2 6 1 - - - - - - - - - - - a c t - - - - - - - - - t - - - a - - - - - a - - - -
HPV37 Beta-2 8 1 - - - - - - - - - - - t - t a - - - - - - - - t - - a a - - - - - a - c - -
HPV38 Beta-2 7 1 - - - - - - - - - - - t - t a - - - - - c - - t - - a a - - - - - - - - - -
HPV122 Beta-2 6 1 - - - - - - - - - - - t - t g - - - - - - - - t - - - a - - - - - - - a - -
HPV174 Beta-2 9 0 - - - - - - - - - - - - c t g - - - - - - - - t - - a a - a - - - a - a - -
HPV75 Beta-3 7 1 - - - - - - - - - - - a - - - - - - - a a - - t - - a t - a - - - - - - - -
HPV115 Beta-3 8 1 - - - - - - - - - - - a - - c - - - - a a - - t - - - c - t - - - - - c - -
HPV142 Gamma-10 6 1 - - - - - - - - - g - - c t a - - - - - - - - - - - - c - - - - - - - a - -
HPV161 Gamma-19 5 1 - - - - - - - - - - - a - - - - - - - - a - - t - - - t - - - - - - - g - -
HPV165 Gamma-12 6 2 - - - - - c - - - - - t - - - - - - - - - - - - a - t t - a - - - - - - - -
*HPV types also found in eyebrow samples. I, inosine; Tm, melting temperature.
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assay is able to identify multiple HPV types, even from dif-
ferent genera, in the same clinical sample. Moreover,
sequences representing 27 novel putative HPV types were
identified. These results demonstrate that the modified pan-
PV CODEHOP PCR is an excellent tool for HPV screening
and identification of novel cutaneous HPVs, even in sam-
ples with low viral loads.
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